Figure 2. CD11b⁺Ly6G⁺ IMCs are the predominant source of Hdc-EGFP expression in the bone marrow.

(a) The left panel shows the percentage of EGFP⁺ cells within the bone marrow (BM), spleen, and peripheral blood of Hdc-EGFP mice; the right panel shows the relative proportion of CD11b⁺ and Gr-1⁺ cells gated from the EGFP⁺ subset respectively.

(b) Expression of CD11b⁺Ly6G⁺ cells. CD11b⁺Gr-1⁺ myeloid cells were gated from the bone marrow of Hdc-EGFP mice. FACS analysis here indicates the proportion of EGFP⁺ cells that were CD11b⁺Gr-1⁺Ly6G^high, CD11b⁺Gr-1⁺Ly6G^mid, and CD11b⁺Gr-1⁺Ly6G⁻ cells. This figure shows representative data from five experiments.

(c) Analysis of peritoneal exudative cells (PECs). Approximately 12% of EGFP⁺ were detected in the PEC by FACS. CD11b⁺Gr-1⁺ (28%) and CD11b⁺Gr-1⁻ (47%) myeloid cells were the major EGFP⁺ cells. Approximately 15% of EGFP⁺ cells expressed mast cell markers: c-kit⁺FcεR⁺.

(d) Differentiation of splenic Hdc-EGFP⁺ IMCs. Immunofluorescence of DAPI stained EGFP⁺ CD11b⁺Ly6G⁺ IMCs treated with or without G-CSF for 48 hours showed suppression of EGFP expression with granulocyte differentiation (The pictures show representative data from three independent experiments).